Application 203611
- Type
- ANDA
- Sponsor
- ACTAVIS ELIZABETH
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | GABAPENTIN | GABAPENTIN | TABLET; ORAL | 300MG | No | No |
| 002 | GABAPENTIN | GABAPENTIN | TABLET; ORAL | 600MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A203611-001 | GABAPENTIN | GABAPENTIN | 300MG | TABLET / ORAL | AB2 | 2026-06-23 | |
| A203611-002 | GABAPENTIN | GABAPENTIN | 600MG | TABLET / ORAL | AB2 | 2026-06-23 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A203611-001 | AB2 |
| A203611-002 | AB2 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A203611-001 | GABAPENTIN | 300MG | TABLET / ORAL | AB2 | 2026-06-23 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A203611-002 | GABAPENTIN | 600MG | TABLET / ORAL | AB2 | 2026-06-23 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A203611-001 | GABAPENTIN | 300MG | TABLET / ORAL | AB2 | 2026-06-23 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A203611-002 | GABAPENTIN | 600MG | TABLET / ORAL | AB2 | 2026-06-23 | caaa826d4ba7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A203611-001 | GABAPENTIN | 300MG | TABLET / ORAL | AB2 | 2026-06-23 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A203611-002 | GABAPENTIN | 600MG | TABLET / ORAL | AB2 | 2026-06-23 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A203611-001 | AB2 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A203611-002 | AB2 | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A203611-001 | AB2 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A203611-002 | AB2 | 1 | caaa826d4ba7… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A203611-001 | AB2 | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A203611-002 | AB2 | 1 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Gabapentin | GABAPENTIN | Proficient Rx LP | 22f2294f-352a-4515-87c8-a6ae46e61322 | 2023-05-01 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| GABAPENTIN | GABAPENTIN | Exelan Pharmaceuticals Inc. | 323dad14-ded9-4432-a265-c957e46cc6db | 2023-03-23 | Warnings, Adverse reactions | GABAPENTIN GABAPENTIN |
| Gabapentin | GABAPENTIN | Proficient Rx LP | 35004f84-90ae-45f0-a2ba-653dec507229 | 2023-03-01 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Cipla USA Inc. | 7c3ac86f-b8f7-42bf-942a-db854d946e54 | 2023-01-20 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Proficient Rx LP | f7a943ec-9a13-45ba-9bc5-18162b86b921 | 2023-01-01 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | 20e48004-d8b6-40fd-929b-b95087b4d85d | 2022-11-28 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Proficient Rx LP | c7cb37f9-e1df-4e2a-bde5-9bfa0e040d7a | 2022-11-01 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | 88ac51c4-5fa9-4c35-9c63-f26bcb101d4b | 2022-10-18 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Asclemed USA, Inc. | e89a7ff2-bd82-4fde-b2b7-3b9d0edf6fc8 | 2022-10-12 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Asclemed USA, Inc. | 9d544944-ea95-42e1-8c65-9e442437f0ee | 2022-10-10 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Proficient Rx LP | f651a143-3f88-49c9-b5c4-c9af55aea76a | 2022-10-01 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Proficient Rx LP | 176c5b60-93c2-4574-8b51-c15180912aaa | 2022-08-01 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Neurontin | GABAPENTIN | Parke-Davis Div of Pfizer Inc | ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388 | 2022-07-12 | Warnings, Adverse reactions | GABAPENTIN |
| Gabapentin | GABAPENTIN | Asclemed USA, Inc. | 14b1840d-a2db-4eec-bc25-029e35b042e4 | 2022-07-09 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Asclemed USA, Inc. | c18d9d06-f796-4eb7-8fd5-1de4ebb95439 | 2022-07-07 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| GABAPENTIN | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | 17988b64-723c-488d-befd-3e4e4cc44bd2 | 2022-05-11 | Warnings, Adverse reactions | GABAPENTIN GABAPENTIN |
| Gabapentin | GABAPENTIN | Proficient Rx LP | ed22b78e-93ff-4cb5-9c9c-2afe9b60dd2e | 2022-05-02 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Proficient Rx LP | 645824d0-eb3d-442b-806d-36a70796cb8e | 2022-05-01 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| GABAPENTIN | GABAPENTIN | Proficient Rx LP | aa3ab216-372a-4a72-bfd1-88a1ffa31ba3 | 2022-05-01 | Warnings, Adverse reactions | GABAPENTIN GABAPENTIN |
| Gabapentin | GABAPENTIN | Proficient Rx LP | b67b7865-df64-429a-9550-5333b9c713ea | 2022-04-01 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.